22 January 2015
Omega Pharma and NovaMedica to market a line of gastrointestinal products under BenegastTM brand in Russia
Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.
“Partnering with Omega Pharma is in line with NovaMedica’s strategy and our focus on delivering innovative treatments for gastrointestinal (GI) patients. The Benegast portfolio has strong synergies with NovaMedica’s current line of GI pharmaceutical products,” said Sergey Beloborodov, Executive Director of NovaMedica LLC. “Benegast products have been marketed successfully in Europe and are ready for fast-track launch in Russia. This is the first umbrella brand solution to address most common symptoms in gastroenterology, and we are confident of its commercial success.”
“We see the serious market potential for Benegast products in Russia, and we are glad that our partnership with NovaMedica will allow the Russian population to gain access to innovative GI products, to feel their efficacy and to improve quality of life,” noted Irina Moustiatsa, Country Manager of Omega Pharma in Russia.
NovaMedica plans to start marketing Benegast products in January 2015. NovaMedica intends to actively promote Benegast products to pharmacies throughout Russia, and will launch a national advertising campaign.
Key products in the portfolio include:
Benegast Reduflux, which contains the proprietary compound Phycodol that provides fast and sustainable relief from heartburn and indigestion. Phycodol, made of high quality extract from brown algae, forms a superior protective barrier on top of the stomach content to instantly suppress acid reflux while preventing pain and discomfort. Available in the form of peppermint flavored chewable tablets.
Benegast Redugas reduces bloating and restores healthy gut flora, thanks to its key ingredient Lycosyl, an effective combination of Simethicone and prebiotics (Inulin). Simethicone physically destroys gas bubbles, while prebiotics restore a healthy gut flora, thus reducing new gas build-up. Available in the form of peppermint-flavored chewable tablets.
Benegast Regulamine contains Chiasyll, a combination of two types of soluble and insoluble fibers to restore and maintain regularity. Chiasyll is the unique combination of Psyllium Husk with Chia Seed for a synergistic effect. Together the two types of fibers form a lubricating gel on the intestines to ease the transit and allow a stronger bulking effect to speed up transit time. These effects restore regularity and eliminate constipation. Available in the form of orange flavored powder in stick-sachets.
NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and Russian investment corporation RUSNANO, which implements government policy of fostering the development of hi-tech industries. The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies in the Russian market, including screening and registration of new pharmaceuticals, and the creation of innovative GMP-standard manufacturing facilities. www.novamedica.com
Omega Pharma is an OTC healthcare company headquartered in Nazareth, Belgium with operations in 35 countries across Europe and select emerging markets. Its products are sold across an extensive network of pharmacies and related retail outlets. With over 2,500 employees, the Company generated sales of more than €1.2 billion in 2013, with more than half of these sales made by its top 20 brands. www.omega-pharma.comPrint
21 February 2019
21 February 2019
Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
20 February 2019
20 February 2019